RORgamma Modulators 2016: A comparative Analysis of the Landscape of RORgamma Antagonists and Agonists

Description: "RORgamma Modulators 2016: A comparative analysis of the landscape of RORgamma Antagonists and Agonists"

Retinoic acid-related orphan nuclear receptor gamma (RORgamma) is a hot, but difficult-to-drug target. More than 30 companies are active in drug discovery and development. Technology companies with expertise in discovery of drugs targeting nuclear hormone receptors are preferred partners of Big Pharma and Biotech companies if they have identified novel scaffolds of RORgamma antagonists. More than ten such technology-pharma partnerships have been founded and already lead to first successes. Three RORgamma antagonists (inverse agonists) are already in clinical development and more to follow in 2016 and thereafter.

The report explains the scientific rationale for discovering antagonists of RORgamma for treatment of autoimmune and inflammatory diseases, but also of agonists of RORgamma for treatment of cancer. Clinical as well as non-clinical data for target validation of RORgamma are provided. Lead and up-side indications for development including the key product profile are discussed. Potential safety concerns for novel RORgamma modulators were identified.

Drug discovery approaches of technology and pharmaceutical companies are shown regarding strategies in partnering as well as in technologies applied for structure-based drug discovery. Based on the experience in the past, estimates of the required time from start of a discovery program of RORgamma modulators until entry into human studies are calculated. The competitive landscape of RORgamma modulator development and discovery projects is analyzed and the profiles of companies elaborated, separately for unpartnered technology or pharmaceutical companies and for partnerships between technology and pharmaceutical companies.

The report provides an understanding of:

- The target RORgamma
- Clinical and non-clinical target validation
- Clinical lead and up-side indications
- Drug discovery strategies and technologies
- Commercial value of drug discovery collaborations
- R&D timelines from start of screening to first-in-human studies
- Competitive landscape of RORgamma antagonists
- Agonists of RORgamma for cancer
- Profiles of unpartnered technology companies and lead projects
- R&D Partnerships and their discovery approaches and lead molecules
- Unpartnered pharmaceutical companies and their programs

Contents:

1. Introduction

2. Executive Summary

3. Target Background

4. Target validation
   - Clinical Success of Anti-IL17 Antibodies
   - Non-Clinical Target Validation
   - Clinical Lead Indication for RORgamma Antagonists
   - Target-related Potential Safety Concerns

5. Drug Discover Approaches & Technologies
   - Drug Discovery Collaboration
6. Competitive Landscape of RORgamma Modulators
- RORgamma Antagonists for Inflammatory and Autoimmune Diseases
- Agonists of RORgamma for Cancer

7. Corporate Stakeholders
- Unpartnered Technology Companies
- Partnerships
- Unpartnered Pharmaceutical Companies

8. References

List of Tables

Table 1: Disease Models Used for Non-Clinical Studies of RORgamma Antagonists
Table 2: Overview of Non-Clinical Studies of RORgamma Antagonists in Psoriasis Models
Table 3: Overview of Non-Clinical Studies of RORgamma Antagonists in Multiple Sclerosis Models
Table 4: Overview of Non-Clinical Studies of RORgamma Antagonists in Arthritis Models
Table 5: Overview of Non-Clinical Studies of RORgamma Antagonists in Inflammatory Bowel Disease and Ulcerative Colitis Models
Table 6: Overview of Non-Clinical Studies of RORgamma Antagonists in Systemic Lupus Erythematosus Models
Table 6: Overview of Partnership Agreements for RORgamma Modulators
Table 7: Special Collaborations for Discovery of RORgamma Antagonists
Table 8: Financial Terms of Partnership Agreements for RORgamma Modulators
Table 9: R&D Timeline for Discovery of RORgamma Antagonists in Partnership Programs
Table 10: Technologies for Discovery of RORgamma Antagonists
Table 11: RORgamma(T) Antagonists/Inverse Agonists in Clinical Development
Table 12: RORgamma(T) Antagonists/Inverse Agonists in pre-IND Studies
Table 13: RORgamma(T) Antagonists/Inverse Agonists in Preclinical R&D
Table 14: RORgamma(T) Antagonists/Inverse Agonists Discovery Programs
Table 15: RORgamma Agonists Discovery & Development Programs
Table 16: Technology and Pharma Companies with RORgamma Modulator R&D

Ordering:
Order Online - http://www.researchandmarkets.com/reports/3612142/
Order by Fax - using the form below
Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit
http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: RORgamma Modulators 2016: A comparative Analysis of the Landscape of RORgamma Antagonists and Agonists
Web Address: http://www.researchandmarkets.com/reports/3612142/
Office Code: SCD21WVU

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Product Format</th>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User:</td>
<td></td>
<td>USD 1087</td>
</tr>
<tr>
<td>Electronic (PDF) - Site License:</td>
<td></td>
<td>USD 2173</td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide:</td>
<td></td>
<td>USD 3260</td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: Mr. [ ]  Mrs. [ ]  Dr. [ ]  Miss [ ]  Ms [ ]  Prof [ ]
First Name: ___________________________________________ Last Name: ___________________________________________
Email Address: * ___________________________________________
Job Title: ___________________________________________
Organisation: ___________________________________________
Address: ___________________________________________
City: ___________________________________________
Postal / Zip Code: ___________________________________________
Country: ___________________________________________
Phone Number: ___________________________________________
Fax Number: ___________________________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:
Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: ____________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World